Enlivex Therapeutics Enters Agreement For Registered Direct Offering Of 3.57M Ordinary Shares And Milestone-Linked Warrants, Raising $5M Upfront And Up To $10M From Warrant Exercises
Portfolio Pulse from Benzinga Newsdesk
Enlivex Therapeutics has entered into an agreement for a registered direct offering of 3.57 million ordinary shares and milestone-linked warrants, raising $5 million upfront and potentially up to $10 million from warrant exercises.
May 28, 2024 | 12:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Enlivex Therapeutics has announced a registered direct offering of 3.57 million ordinary shares and milestone-linked warrants, raising $5 million upfront and potentially up to $10 million from warrant exercises.
The direct offering will provide Enlivex Therapeutics with immediate capital of $5 million and potentially up to $10 million from future warrant exercises. This influx of funds can support the company's operations and growth initiatives, likely having a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100